SCHEMBL19364856

SCHEMBL19364856

O=C(Nc1cncc(F)c1)N1c2nc(N3CCCC(C(F)(F)F)C3)ccc2N2CCC[C@@H]1C2

nearest known ligand 0.40

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
▸ TRPV3 Q8NET8 2/20 0.40
▸ MAP4K4 O95819 1/20 0.39
▸ DGAT2 Q96PD7 1/20 0.36
▸ SCN10A Q9Y5Y9 1/20 0.36
▸ EIF2AK4 Q9P2K8 1/20 0.34
▸ PIM2 Q9P1W9 3/20 0.34
▸ EGFR P00533 1/20 0.34
▸ LCK P06239 1/20 0.34
▸ JAK3 P52333 1/20 0.34
▸ KMT2A Q03164 1/20 0.34
▸ NAMPT P43490 1/20 0.33
▸ BTK Q06187 1/20 0.33
▸ PIM1 P11309 2/20 0.33
▸ POLB P06746 1/20 0.33
▸ SHMT2 P34897 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17624528 1.00 TRPV3 (0.40) TRPV3MAP4K4DGAT2SCN10AEIF2AK4
SCHEMBL19670193 1.00 TRPV3 (0.40) TRPV3MAP4K4DGAT2SCN10AEIF2AK4
SCHEMBL17624461 0.98 TRPV3 (0.40) TRPV3MAP4K4DGAT2SCN10AEIF2AK4
SCHEMBL17624527 0.91 TRPV3 (0.40) TRPV3MAP4K4DGAT2SCN10AEIF2AK4
SCHEMBL19364858 0.91 TRPV3 (0.40) TRPV3MAP4K4DGAT2SCN10AEIF2AK4
SCHEMBL19670191 0.91 TRPV3 (0.40) TRPV3MAP4K4DGAT2SCN10AEIF2AK4
SCHEMBL19364922 0.89 SCN10A (0.41) TRPV3MAP4K4SCN10APIM2POLB
SCHEMBL17624470 0.89 SCN10A (0.41) TRPV3MAP4K4DGAT2SCN10AEIF2AK4
SCHEMBL19670286 0.88 TRPV3 (0.40) TRPV3MAP4K4DGAT2SCN10AEIF2AK4
SCHEMBL17624478 0.88 TRPV3 (0.40) TRPV3MAP4K4DGAT2SCN10AEIF2AK4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10590135-B2 Substituted bridged urea analogs as sirtuin modulators GLAXOSMITHKLINE LLC (US) 2020-03-17 — — US disclosed
US-20170355697-A1 SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS GLAXOSMITHKLINE LLC 2017-12-14 — — US disclosed
US-20170355697-A1 SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS GLAXOSMITHKLINE LLC 2017-12-14 — — US disclosed
US-9834558-B2 Substituted bridged urea analogs as sirtuin modulators GLAXOSMITHKLINE LLC (US) 2017-12-05 — — US disclosed
US-9834558-B2 Substituted bridged urea analogs as sirtuin modulators GLAXOSMITHKLINE LLC (US) 2017-12-05 — — US disclosed
US-9765075-B2 Substituted bridged urea analogs as sirtuin modulators GLAXOSMITHKLINE LLC (US) 2017-09-19 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170355697-A1 SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS SIRT1, SIRT3, SIRT2 TRPV3 4093/4885MAP4K4 2229/4885DGAT2 1047/4885
US-10590135-B2 Substituted bridged urea analogs as sirtuin modulators SIRT1, SIRT3, SIRT2 TRPV3 4093/4885MAP4K4 2229/4885DGAT2 1047/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback